Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Polysaccharide Diphtheria Toxoid Conjugate Vaccine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

NCT01482052
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
meningococcal meningitis conjugate vaccine, quadrivalent
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hanford, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047
View directory record Official record
Conditions
Diphtheria, Polio, Pertussis
Interventions
DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
36
States / cities
Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

NCT01659996
View directory record Official record
Conditions
Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions
Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 18 Months
Enrollment
1,394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

NCT03077438
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Years to 9 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
35
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine

NCT00164411
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Tetanus-diphtheria toxoids (Td), 7-valent pneumococcal conjugate vaccine, 23-valent polysaccharide vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
50 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 10, 2026, 1:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

NCT01689155
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

NCT01897402
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
Test Vaccine, US Licensed Vaccine
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Greenbelt, Maryland • Pasadena, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

NCT00282295
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Boostrix®, Menactra™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
24
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 10, 2026, 1:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

NCT00254995
View directory record Official record
Conditions
Meningitis, Meningococcal Disease
Interventions
None administered in this study
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
62,626 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

NCT02810340
View directory record Official record
Conditions
Meningococcal Vaccines
Interventions
Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

NCT02842853
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 55 Years
Enrollment
3,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
89
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03673462
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,797 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
67
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03691610
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 19 Months
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

NCT00258856
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Polysaccharide Diphtheria Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
7 Years to 15 Years
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
11
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Marietta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Results available

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

NCT02097849
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

NCT00269477
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 23 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
8
States / cities
Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

NCT00483574
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

NCT00197236
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix™, Infanrix™, ActHIB™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
22
States / cities
Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 10, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of GBS Colonization Via Immunity

NCT00128219
View directory record Official record
Conditions
Beta Haemolytic Streptococcal Infection
Interventions
GBS III-TT, Tetanus and diptheria toxoids vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 10, 2026, 1:20 AM EDT